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Introduction
Tumorigenesis comprises multiple processes with a stepwise accumulation of genetic alterations that drive the progressive transformation of normal cells into highly malignant derivatives 1 .
Recent studies of a large number of genomes in human cancer tissues clarified that cancer cells generally possess hundreds of somatic mutations and dysregulated gene expression profiles [2] [3] [4] .
Although the origin of cancer cells remains mostly unsolved at present, it might be difficult for fully differentiated cells to acquire these large numbers of nucleotide alterations during their limited life span to achieve malignant transformation. In contrast, stem/progenitor cells have a long lifetime in order to supply the differentiated progenies in each organ. Thus, it appears reasonable to assume that long-lived tissue stem/progenitor cells can accumulate genetic alterations and hence could be the origin of tumor cells. Consistent with this hypothesis, a number of studies have provided evidence that the mutations would most likely result in expansion of the altered stem cells, perpetuating and increasing the chances of additional mutations, leading to malignant transformation [5] [6] [7] [8] .
Several studies have provided evidence that hepatocellular carcinoma (HCC) might originate from hepatic stem/progenitor cells [9] [10] [11] [12] . A histologic study of clinical specimens also revealed that a substantial number of human HCC tissues have bipotential characteristics with coexpression of biliary and hepatocytic markers such as cytokeratin 7 (CK7), CK19, alpha-fetoprotein (AFP), and albumin 13, 14 . Conversely, all cholangiocarcinoma tissues examined showed hepatocellular differentiation in part of the tumor and expression of hepatic progenitor cell markers 15 . Findings from a recent study also suggested that human HCC could arise as a consequence of the dysregulated proliferation of hepatic progenitor cells when the TGF-β and IL-6 signaling pathway was disrupted 16 . 6 Activation-induced cytidine deaminase (AID) can induce genetic alterations in human genome DNA sequences 17, 18 . Under physiological condition, AID is expressed almost exclusively in B lymphocytes, and plays a critical role not only in class switch recombination but also in somatic hypermutation of immunoglobulin genes. We recently demonstrated that inflammatory stimulation triggers aberrant AID expression in epithelial cells and initiates and/or promotes oncogenic pathways by inducing genetic alterations in various tumor-related genes 19, 20 . Indeed, AID expression is induced by proinflammatory cytokine stimulation and/or hepatitis C virus infection through NF-kB activation in hepatocytes 21 , and the resultant AID upregulation leads to the accumulation of somatic mutations in TP53 and c-MYC genes, both of which are frequently mutated in human cancer tissues 21, 22 . These findings suggest that aberrant AID production induced by chronic inflammation in the liver contributes to hepatocarcinogenesis via the accumulation of genetic aberrations in tumor-related genes 23 .
The fact that it usually takes over a year for AID transgenic (Tg) mice to accumulate the genetic aberrations required for carcinogenesis 24, 25 prompted us to speculate that constitutive expression of AID in the cells with long life-span might possess the higher risk for malignant transformation compared to that in the cells with the limited life-span. Therefore, in the present study, we took advantage of the AID-mediated stepwise genotoxicity that recapitulates human hepatitis-associated carcinogenesis to investigate whether liver cancer originates from fetal hepatic progenitor cells with constitutive AID expression. Accordingly, we separated hepatic progenitor cells enriched from the fetal liver of AID Tg mice followed by transplantation into recipient mice and examined whether recipient mice receiving AID-expressing hepatic progenitor cells develop liver tumors. Furthermore, to unveil the overall landscape of genetic 7 alterations that accumulate in hepatic progenitor cells during the process of malignant transformation, we applied whole exome sequencing and determined the whole picture of genetic aberrations that accumulated in liver cancer cells originating from hepatic stem/progenitor cells.
Materials and Methods

Animals
The "toxin-receptor mediated conditional cell knockout" mice, which are homozygous for the albumin enhancer/promoter driven-human heparin binding epidermal growth factor-like growth factor (hHB-EGF) alleles, achieve the specific and conditional ablation of hepatocytes under the treatment of diphtheria toxin (DT) 26 . AID Tg mice were previously described 24 . All animals were maintained in a specific pathogen-free facility at the Kyoto University Faculty of Medicine.
All animal experiments were approved by the ethics committee for animal experiments and performed under the Guidelines for Animal Experiments of Kyoto University.
Isolation of enriched hepatic progenitor cells, cell transplantation, and administration of diphtheria toxin
Hepatic progenitor cells were obtained from the fetal liver of pregnant wild-type, AID Tg , and green fluorescent protein (GFP) Tg mice on gestational day 13.5 and were enriched through sphere formation as previously described 27 . Briefly, after the digestion of fetal liver tissues using a 0.5% collagenase solution (Invitrogen, Carlsbad, CA), fetal liver cells were subjected to floating culture to form spheres in RPMI 1640 (Invitrogen) supplemented with 10% fetal calf serum. After 16 h incubation, the formed spheres were selected by gravity sedimentation and inoculated on type-I collagen-coated culture plates (Asahi Glass, Co., Ltd., Chiba, Japan). After 24 h of incubation, floating hematopoietic cells were removed by washing and adhered cells 8 were collected using trypsin-ethylenediaminetetraacetic acid (EDTA) solution (Sigma-Aldrich Co., Ltd., St. Louis, MO) for 3 min. The dissociated cells were counted and suspended in a Ca 2+ -free Hank's balanced salt solution (Invitrogen) with fetal calf serum at a density of 5.0 x 10 6 cells/ml as the enriched hepatic progenitor cells. To characterize the enriched hepatic progenitor cells, expression levels of fetal liver stem/progenitor markers, including albumin, AFP, DLK1, CK19, and CD133, were examined using both immunohistochemistry and RT-PCR. In addition, the lack of expression of the hematopoietic cell marker CD45 in sphere-derived hepatic progenitor cells was also confirmed by both immunostaining and RT-PCR.
To achieve efficient engraftment of transplanted hepatic progenitor cells to livers of the recipient mice, we used TRECK mice as a liver-specific regeneration model 26 . TRECK mice express DT receptor under control of the albumin promoter, and treatment with DT selectively and efficiently ablates the hepatocytes, resulting in enhanced liver regeneration and efficient colonization of transplanted hepatic progenitor cells 27 . The enriched hepatic progenitor cells were transplanted into 7-to 9-wk old TRECK mice using an intrasplenic approach 27, 28 . We injected 0.2 ml of a cell suspension containing 1.0 x 10 6 hepatic progenitor cells. The DT was purified as described previously 26 and a total of 75 ng/kg DT was administered by intraperitoneal injection into recipient mice twice a week for 25 wk from the day of cell transplantation.
Whole exome capture and massively-parallel sequencing
Massively-parallel sequencing was performed using the Illumina Genome Analyzer IIx (Illumina, San Diego, CA) as described 29 . End-repair of DNA fragments, addition of adenine to the 3' ends of DNA fragments, adaptor ligation, and PCR amplification were performed according to the instructions. Exome capture was performed according to the NimbleGen Arrays Users Guide Cluster generation and sequencing was performed for 76 cycles on the Illumina Genome Analyzer IIx as described using the pair-end protocol and collecting 76 bases from each read 29 .
The obtained images were analyzed and base-called using GA pipeline software version 1.4 with the default settings provided by Illumina. All sequence reads were deposited in the DNA Data Bank of Japan Sequence Read Archive; accession number DRA000601.
RNA preparation and hybridization to the microarray
Total RNA was extracted from adult mice (12 wk old) liver tissues, bone marrow, and the fetal liver at day 13.5 of gestation using RNeasy Mini Kit (Qiagen, Valencia, CA). The details of the procedures for hybridization to the microarray were described previously 30 . RNA amplification and labeling were performed according to the manufacturer's instructions (Agilent Technologies, Palo Alto, CA). Array image acquisition and feature extraction were performed using an Agilent G2505C scanner with feature extraction software (Agilent Technologies). Microarray data were deposited in the GEO database; accession number GSE39213.
Genome Analyzer sequence data analysis and variant filtering.
Semiquantitative reverse transcription PCR and quantitative real-time genomic and reverse transcription-PCR
Histology and immunohistochemistry
Southern blot analysis
Statistical analysis
These procedures are described in Supplementary Materials and Methods [31] [32] [33] .
Results
Enrichment of hepatic progenitor cells derived from fetal mouse liver
Enriched hepatic progenitor cells were obtained from the fetal liver of wild-type, AID Tg and GFP Tg mice through the formation of cell spheres, and the dissociated cells were cultured, counted, and then transplanted into recipient mice ( Figure 1A ). To characterize the sphere-derived hepatic cells used for the transplantation procedure, we first examined the expression of various marker genes in the fetal liver of wild-type mice. Immunohistochemistry revealed that expression of both the liver cell marker albumin and the hematopoietic cell marker CD45 were detectable in the fetal liver tissues ( Figure 1B ). Cells expressing DLK1, a cell surface marker for hepatic stem/progenitor cells, comprised ~10% of the total cells of the fetal liver parenchyma ( Supplementary Figure 2A ). The enriched cell population specifically contained cells expressing the hepatocyte-lineage cell markers such as albumin and AFP, but no expression of CD45 was detectable in these sphere-forming cells ( Figure 1C ). In addition, we 11 confirmed that almost the entire enriched sphere-derived cell population expressed E-cadherin and DLK1, and a subset of those enriched cells expressed CK19 and CD133 (Supplementary Figure 2B ). On the other hand, the floating cells that did not form spheres strongly expressed CD45 ( Figure 1D ). RT-PCR also revealed that the sphere-forming cells prepared for the transplantation procedure expressed albumin, AFP, DLK1, CK19, and CD133 transcripts, but not CD45 ( Figure 1E ). Similar results were obtained in the fetal liver of AID Tg mice (data not shown). These expression profiles of the collected sphere-derived cells were consistent with those found in previous studies 34 and indicated that the enriched cells derived from the fetal liver fully contained hepatic lineage progenitor cells.
Efficient engraftment of transplanted hepatic progenitor cells in the recipient liver
To enhance engraftment of the transplanted cells in the liver, we used TRECK mice as a liver-specific regeneration model. These mice express hHB-EGF precursor, which functions as a DT receptor, under the control of an albumin promoter, and thus the hepatocytes of these mice are selectively ablated by the administration of DT 26 . We confirmed that the transcripts of hHB-EGF were specifically detectable in the liver of the TRECK mice ( Figure 2A ), and immunohistochemistry also revealed that hHB-EGF protein expression was present in the TRECK mouse liver tissues ( Figure 2B ). Serum alanine aminotransferase levels of a TRECK mouse were increased at 24 h after 75ng/kg of DT administration, peaked at 48 to 72 h, and subsequently returned to basal levels after 120 h ( Figure 2C ). After repeated trials, we found that twice-weekly DT administration maintained the sublethal liver injury, resulting in the constitutive hepatic regeneration process. Under these experimental conditions, DT-mediated ablation of hepatocytes in TRECK mice resulted in the expansion of cells expressing E-cadherin, EpCAM, and HNF4α accompanied by an increased number of the Ki67-positive cells, suggesting enhanced proliferation activity of hepatocyte-lineage cells including hepatic progenitor cells and mature hepatocytes in the TRECK liver tissues ( Figure 2D , and data not shown).
To examine the repopulation of the transplanted cells in the recipient liver, the hepatic progenitor cells of the GFP Tg fetal livers obtained in a similar way were introduced into the TRECK mice, followed by the repeated DT administration. At day 7, the GFP-positive cells were observed as clusters, and at day 30 the cluster of the GFP-positive cells was large enough to view macroscopically ( Figure 2E ). Moreover, the cluster of hepatocytes derived from the transplanted GFP-positive enriched hepatic progenitor cells was detectable in the recipient liver even 90 days after the transplantation while no such cells were observed in the liver of mice without DT administration ( Figure 2F ). These findings indicated that the transplanted cells efficiently engrafted and continued to proliferate in the recipient livers treated with DT as time progressed.
Transplanted hepatic progenitor cells with constitutive AID expression progressed to liver cancers.
Next, the enriched hepatic progenitor cells from AID Tg mice were transplanted into 13 recipient (TRECK) mice, and the DT was administered to the recipient mice for 25wk. Two mice died in a week after transplantation, while the remaining 11 mice were viable and thus subjected to phenotypic analyses. We found that liver tumors developed in 7 of 11 (63.6%) recipient mice that received the enriched hepatic progenitor cells of the AID Tg mice 90 wk after cell transplantation ( Figure 3A ). Among them, four mice developed multiple tumors and three developed a single large nodule. On the other hand, none of the 13 recipient mice receiving hepatic progenitor cells from wild-type or GFP Tg mice showed tumorigenesis during the same observation period, while 13 only one mouse developed a tumor with the characteristics of lipoma. Moreover, all the five recipient mice examined that received the mature hepatocytes of adult AID Tg mice at 6 months of age showed no phenotypic changes in the liver tissues. Histologic examination revealed that all the tumors examined showed the characteristics of well-to-moderately differentiated HCC.
Interestingly, one tumor showed not only the enhanced AFP expression but also the ductal To examine whether the cancers that developed in recipient mice liver were derived from the transplanted hepatic progenitor cells, we examined the expression of the AID Tg mice-specific transgene in three randomly selected tumors that developed in the recipient livers. Southern blotting analyses revealed strong signals of the AID transgene in the tumor tissues ( Figure 3C ).
Weak signal of the AID transgene was also detected in the non-tumorous region, suggesting continuous engraftment of the transplanted hepatic progenitor-derived cells in the recipient mouse liver. In contrast, there were no detectable signals of the AID transgene in organs other than the liver of recipient mice, such as kidney, or in liver tissues of the TRECK mice without receiving the transplantation. Quantitative genomic PCR analyses also confirmed that all tumor tissues examined strongly expressed the AID transgene ( Figure 3D ). Moreover, the expression level of hHB-EGF in the tumor tissue was significantly lower than that in the surrounding non-tumorous liver tissue (Supplementary Figure 2C) . These findings suggested that the transplanted hepatic progenitor cells with constitutive AID expression achieved the malignant transformation and progressed to either HCC or cholangiocarcinoma.
Landscape of genetic alterations accumulated in the transplanted hepatic progenitor cells during the process of malignant transformation.
To unveil the landscape of genetic alterations that accumulated in the transplanted hepatic progenitor cells during the process of tumorigenesis, we determined the sequences of the whole exome in two independent liver cancers from two different recipient mice and the corresponding hepatic progenitor cells of the same AID Tg mice from which they originated (Table1). As a control, we also determined the whole exome sequences of the livers of their littermates with a wild-type phenotype. A total of 94.2% of the reads were properly aligned to the reference mouse genome and accordingly we obtained about 4.4 Gb of the aligned sequence data per sample on average after exome enrichment. 77.6% of the captured target exons were covered by 20X or more coverage depth read with a high quality genotype call. The variant filtering process is summarized in Supplementary Figure 1 . We identified 24 (23 single nucleotide variants [SNVs] and 1 indel) and 162 (160 SNVs and 2 indels) somatic mutations in HCC#1 and HCC#2, of which the number of mutated genes with SNVs were 23 (HCC#1) and 105 (HCC#2), respectively ( Table 2, and Supplementary Table 4 ). As shown in Supplementary Figure 2D , C/G to T/A substitution pattern was dominant, consistent with the previous finding that AID induces C/G to T/A transition into the genome 23, 24 . The candidate variants were then validated by conventional direct population Sanger sequencing ( Supplementary Figure 3) , and we finally confirmed that 20 (HCC#1) and 87 (HCC#2) SNVs were nonsynonymous variants. Among them, there were no genes commonly mutated in both tumors. Interestingly, 19 of 23 (82.6% in HCC#1) and 80 of 105 (76.2% in HCC #2) genes with SNVs were those reported in human liver 15 cancer tissues (International Cancer Genome Consortium; http://www.icgc.org/). Although tumor-suppressor Trp 53 gene also acquired mutations in both tumors, the nucleotide alteration rate was less than 20%. Pathway analyses using the KEGG (Kyoto Encyclopedia of Genes and Genomes) database (http://www.genome.jp/kegg/) revealed that 11 (HCC#1) and 66 (HCC#2) genes were categorized into the well-known signaling pathways, including peroxisome proliferator-activated receptor (PPAR) and mitogen-activated protein kinase (MAPK) signaling, and cell adhesion function (Table 3 ).
Although it is widely recognized that the mutational profiles of the tumor-related genes differ between different tissues, the mechanisms of those organ-specific differences in the mutated genes during the process of tumorigenesis remain unclear. We speculated that the genes that acquired mutations in HCC tissues might be preferentially and actively transcribed in hepatic lineage cells, because it has been shown that AID-induced mutagenic activity is directly proportional to the transcription levels of the target gene [35] [36] [37] . Therefore, we analyzed the gene expression profiles in the fetal and adult liver using microarray, and examined whether the mutated genes in HCC tissues were transcribed at relatively higher levels in liver-lineage cells compared with hematopoietic lineage cells. Among the mutated genes identified, transcription levels of 95.4% and 85.8% of the genes in HCC#1 and HCC#2, respectively, were higher in fetal and/or adult liver tissues than in bone marrow-derived hematopoietic cells ( Table 2, and   Supplementary Table 4 ), indicating that the genes actively transcribed in fetal and/or adult liver cells might have preferentially acquired the mutations through the genotoxic activity of AID.
Consistently, quantitative RT-PCR analyses revealed that all the mutated genes analyzed were actively transcribed in adult liver tissues ( Supplementary Figure 4 ). In contrast, representative genes that are actively transcribed in hematopoietic tissues 38 , such as Cd4, Cd5, and Tgfbr2, showed no mutations in liver tumors and less or no transcription in the liver compared with other organs ( Supplementary Figure 4) . We also confirmed that 19 (82.6% in HCC#1) and 93 (88.6% in HCC#2) of the mutated genes were actively transcribed in the liver tissues based on the mouse whole transcriptome analysis 39 .Together, these findings suggest that the acquisition of mutations during hepatocarcinogenesis strongly depends on the transcription of target genes in the liver-lineage cells.
Discussion
Recently, recognition of the role of tissue stem/progenitor cells in the carcinogenesis process led to a new hypothesis that cancer arises from tissue stem/progenitor cells 40 . Indeed, genetically-engineered fetal progenitor cells lacking the tumor-suppressor gene function have been shown to play a role as the origin of liver cancer 9, 11, 41 . Whether the stepwise accumulation of genetic alterations on hepatic stem/progenitor cells contributes to the development of tumor cells, however, remains unknown. In the present study, we demonstrated that engrafted hepatic progenitor cells originated from the AID Tg mice progressed to liver tumors, including both HCC and cholangiocarcinoma, through the accumulation of somatic mutations in a variety of target genes.
Several previous studies demonstrated that the transplanted putative fetal liver stem/progenitor cells are capable of repopulating the liver that encounter extensive liver injury favoring the proliferation and survival of transplanted hepatocytes [42] [43] [44] . The DT receptor has been identified as a membrane-anchored form of the HB-EGF precursor 26 . Recently, it was shown that transplanted hepatic progenitor cells derived from the fetal liver were efficiently engrafted and repopulated in the liver of recipient HB-EGF-expressing mice with DT stimulation 27, 28 . Using this model, efficient engraftment of the transplanted cells in recipient mice with HB-EGF expression in the liver enabled us to examine the fate of transplanted hepatic progenitor cells with constitutive AID expression. Notably, liver tumors with histologic features of human HCC developed in the recipient mice that received the hepatic progenitor cells derived from the AID Tg mice, while no tumorigenesis was observed in the recipient mice transplanted with hepatic progenitor cells of control mice. The findings that the tumors contained the AID transgene indicated that these tumors were derived from the transplanted hepatic progenitor cells accompanied with the AID-induced genetic aberrations. Interestingly, one of those tumors showed both the characteristics of HCC and cholangiocarcinoma in a single nodule, suggesting that the hepatic progenitor cells with the accumulation of genetic aberration could possess the potential to progress both HCC-and cholangiocarcinoma-lineage tumor cells. Alternatively, it might be possible that AID-mediated genetic alterations contribute to modifying the differentiation status of tumor cells, leading to either HCC or bile duct cancers from common progenitor cells.
Sequencing of whole genomes, whole exomes, and whole transcriptomes of cancer samples has recently become feasible using deep sequencing technologies. In this study, to obtain the overall picture of genetic alterations accumulated in the hepatic progenitor cells of the AID Tg mice that achieved malignant transformation, we performed whole exome sequencing of the transplanted progenitor cells and the resultant tumor tissues, and unveiled the landscape of genetic alterations that accumulated during tumorigenesis. We found that various genetic aberrations, mainly SNVs, were highly accumulated in the tumors, further supporting the putative involvement of aberrant AID activity in the development of HCC. One thing to be noted is that approximately 80% of mutated genes detected in the liver cancer tissues developed in the recipient mice have been reported to be mutated in human HCC tissues (International Cancer Genome Consortium; http://www.icgc.org/), although it is not possible to draw a definitive conclusion from analyses of the limited number of HCCs that developed in the recipient mice. Functional annotation analyses revealed that many of the genes that acquired genetic aberrations are categorized into several important signaling pathways, including those involved in the regulation of cell proliferation, cell metabolism, and cell adhesion. Thus, it could be suggested the stepwise dysregulation of cell function caused by the accumulation of genetic aberrations in hepatic progenitor cells appears to play a pivotal role in the development of tumor cells.
We previously revealed that genetic changes induced by the genotoxic activity of AID show organ-specific profiles and suggested the possibility that the target preference of AID-induced mutagenesis contributes to the diversity of tissue-specific oncogenic pathways 23 . One possible explanation for the target selection for mutagenesis is that AID preferentially induces mutations in the actively-transcribed genes in each cell, because AID likely induces somatic mutations on the single-strand DNA exposed during the transcription process [35] [36] [37] . Consistent with this hypothesis, we confirmed in this study that the majority of genes with SNVs were the actively transcribed genes in liver lineage cells. However, we also observed that the transcription level of the gene is not solely responsible for the acquisition of AID-mediated genotoxicity, because one of the most actively transcribed hepatotrophic genes, albumin, did not accumulate SNVs in liver tumor cells (data not shown). Consistently, extensive sequencing of various genes in B lymphocytes revealed that only 25% of the transcribed genes accumulated SNVs in an AID-dependent manner 45 . Mutational hotspots preferentially attacked by AID genotoxicity frequently possess unique sequence characteristics, so-called RGYW/WRCY motifs (where W=A or T, R=A or G, and Y=C or T) in transcribed targets 46 . Moreover, a recent study reported clusters of various types of repeat sequences in the vicinity of cleaved sites in AID target genes 47 .
Thus, target selection of AID-mediated mutagenesis might require both active transcription and sequence characteristics of the genes.
In conclusion, the findings in the present study suggested that mutagenic activity of AID might contribute to the malignant transformation of hepatic progenitor cells to liver cancer cells via the induction of genetic alterations. Some of the actively transcribed genes in the liver-lineage cells preferentially accumulated SNVs and might contribute to the development of tumor cells.
However, based on the model used in the present study, we could not fully determine whether the developed tumors derived directly from the fetal hepatic progenitor cells or via mature hepatocytes, because the transplanted fetal progenitor cells differentiated into mature hepatocytes in the recipient liver 27 . Moreover, the truly significant driver mutations responsible for hepatocarcinogenesis remain unclear. Thus, further elucidation of the precise step of the AID-induced accumulation of genetic aberrations will be required to identify the genetic alterations that possess the key to the carcinogenesis process. In addition, the fractionation by fluorescence-activated cell sorting would be essential to identify the subset of hepatic stem/progenitor cells that play a role in the origin of tumor cells. 
Figure legends
Supplementary Materials and Methods
Genome Analyzer sequence data analysis and variant filtering.
Using the high performance alignment software "NextGENe v2.1" (SoftGenetics, State College, PA), the 76 base-pair reads obtained from the Genome Analyzer IIx were aligned with the reference sequences of Mus musculus whole genome derived from the NCBI build 37.1 annotation. Reads with 96% or more bases matching a particular position of the reference sequences were aligned. Furthermore, two quality filters were used for sequencing reads: reads with a median quality value score of more than 20 and no more than 3 uncalled nucleotides were allowed anywhere in the 76 bases. Only sequences that passed the quality filters, rather than raw sequences, were analyzed and each position of the genome was assigned a coverage depth, representing the number of times the nucleotide position was sequenced. To identify somatic mutations, we used a number of scores developed by SoftGenetics to provide an empirical estimation of the likelihood that a given mutation is real and not an artifact of sequencing or alignment errors. This score is based on the concept of Phred scores, where quality scores are logarithmically linked to error probabilities. The Overall Mutation score is calculated according to the following equation: Overall Mutation score = (Coverage score) x (four optional scores). The four optional scores are the Read balance score, Allele balance score, Mismatch score, and Wrong Allele score. These scores are described in "Next GENe v2.1" in detail. The candidates of somatic mutations were selected according to the variant filtering process ( Supplementary Figure 1) . As we further required that common variants in mice be excluded, the mutations in liver tumors must not be found in more than 5% of the reads in the liver of wild-type C57BL/6 mouse. In addition, the mutations in liver tumors should not be observed in the original corresponding hepatic progenitor cells of the AID Tg mice, therefore nucleotide alterations could not appear in more than 5% of reads in the originating cells. Candidate single nucleotide variants were tested using standard Sanger sequencing on an Applied Biosystems 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA) to validate the presence of each mutation in HCCs and the absence of each in the liver of wild-type mice.
Semiquantitative reverse transcription PCR and quantitative real-time genomic and reverse transcription-PCR
Total RNA was extracted from the tissues using RNeasy Mini Kit (Qiagen). cDNA was synthesized using Transcriptor First-Strand cDNA Synthesis Kit (Roche). The 
Histology and immunohistochemistry
The details of the immunohistochemistry procedures were described previously [31] [32] [33] .
The primary and secondary antibodies used for immunostaining are shown in Supplementary Table 3 .
Southern blot analysis
Southern blot analysis was performed using AlkPhos Direct Labelling Reagents (GE Healthcare, Buckinghamshire, England), with DNA probes labeled using alkaline phosphatase using the following primer and probe sets: AID transgene SB sense; GGACAGCCTTCTGATGAAGC, AID transgene SB antisense; TGGCATATGTTGCCAAACTC, AID transgene probe sense; GGACAGCCTTCTGATGAAGC, AID transgene probe antisense; GAAGTTGTCTGGTTAGCCGG, Actb SB sense; TGTACGTAGCCATCCAG, Actb SB antisense; CCTTCACCGTTCCAGT, Actb probe sense; TGAGCTGCCTGACGG, Actb probe antisense; GCCACCGATCCACACA.
Statistical analysis
Statistical differences in the gene expression levels were analyzed using the Kruskal-Wallis H-test with Bonferroni correction. Total RNA was extracted from the liver, kidney, lung, brain and spleen of the wild-type mice and subjected to quantitative RT-PCR. The expression levels of the mutated (A) and non-mutated (B) genes in the liver cancer tissues are shown. Values shown in the graphs were normalized relative to the expression of the spleen (mean±SE; n=3).
Supplementary Figure legends
Supplementary Table 1.
Primer sequences used for semiquantitative RT-PCR amplification. 
